MedPath

on-hormonal treatment of vaginal atrophy.

Phase 3
Conditions
vaginal atrophy.
Postmenopausal Atrophic Vaginitis
Registration Number
IRCT2013060913611N1
Lead Sponsor
Mashhad Universityof Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
60
Inclusion Criteria

age between 40-65 years old; amenorrhea for at least 12 months, or 6 months after the last menstrual them with FSH> 40; having a normal Pap smear within the past 3 years, or more than 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy; clinical atrophy of the vagina through a set of criteria that includes: PH vagina> 5 and earn a score of 65 or higher (based on a visual analogue scale, VAS) for most bothersome symptoms (MBS) and superficial cells equal or less than 5% and at least two symptoms of Descriptive Assessment Table of Vaginal Mucosa. Exclusion criteria: existing breast or endometrial cancer or suspicion thereof, genital abnormalities; abnormal vaginal bleeding; cardiovascular disease (including coronary heart disease; cerebrovascular disease; thromboembolic disorders); active liver or gallbladder disease; diabetes and blood pressure-lowering drugs; vaginal infection; allergy to estrogen and vitamin E; hormone use during the 8 weeks before the study; the use of 40 to 60 grams phytoestrogens during the day; use of stimuli that can cause chronic itching in the vagina; useing less than 70% of the total number of drug (less than 24 times during the treatment period

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Symptoms of vaginal atrophy. Timepoint: Before intervention, 4, 8 and 12 weeks after intervention. Method of measurement: Description of the vaginal mucosa? vaginal maturation index, the most bothersome symptom of vaginal and vaginal pH.
Secondary Outcome Measures
NameTimeMethod
Superficial cells in the vagina. Timepoint: Befor the intervention? 4? 8 and 12 weeks after intervention. Method of measurement: Vaginal maturation index.
© Copyright 2025. All Rights Reserved by MedPath